Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2013
Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid.
Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 92 citations in OpenAlex.
- Risk factors and clinical significance of refractory pain in patients with bone metastases: a comprehensive meta-analysis.Frontiers in neurology · 2025Pooled it
- Meta-analysis of clinical trials to assess denosumab over zoledronic acid in bone metastasis.International journal of clinical pharmacy · 2021Pooled it
- Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.Health technology assessment (Winchester, England) · 2020Trial
- Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016Trial
- Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events.Annals of oncology : official journal of the European Society for Medical Oncology · 2015Trial
- Utidelone combined with radiotherapy followed by denosumab maintenance in a breast cancer patient with clivus metastasis: a long-term remission case report and literature review.Frontiers in oncology · 2026Article
- Review
- Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval.Journal of bone oncology · 2022Review
- All bone metastases are not created equal: Revisiting treatment resistance in renal cell carcinoma.Journal of bone oncology · 2021Review
- Cancer induced bone pain: current management and future perspectives.Medical oncology (Northwood, London, England) · 2021Review
- Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancer.BJU international · 2021Article
- Observational
- Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches.Breast cancer : basic and clinical research · 2021Review
- Reciprocal interactions between osteoclasts and nociceptive sensory neurons in bone cancer pain.Pain reports · 2021Review
- Advanced renal cell carcinoma (RCC) management: an expert panel recommendation from the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG).Journal of cancer research and clinical oncology · 2020Review
- A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe.Journal of bone oncology · 2019Article
- Advances in pain management for older patients with cancer.Ecancermedicalscience · 2019Review
- Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer.Prostate cancer and prostatic diseases · 2018Article
- Physicians' preferences for bone metastases treatments in France, Germany and the United Kingdom.BMC health services research · 2018Article
- Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries.Journal of bone oncology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 11 institutions in 6 countries.
Funding
Abstract
purposeThis analysis evaluated patient-reported outcomes and analgesic use in patients with bone metastases from solid tumours across three comparative studies of denosumab and zoledronic acid.
methodsPooled data were analysed from three identically designed double-blind phase III studies comparing subcutaneous denosumab 120 mg with intravenous zoledronic acid 4 mg monthly in patients with bone metastases from breast cancer (n = 2,046), castration-resistant prostate cancer (n = 1,901) or other solid tumours (n = 1,597). Pain severity, pain interference, health-related quality of life and analgesic use were quantified.
resultsAt baseline, approximately half of patients had no/mild pain (53 % [1,386/2,620] denosumab; 50 % [1,297/2,578] zoledronic acid). Denosumab delayed onset of moderate/severe pain by 1.8 months (median, 6.5 vs 4.7 months; hazard ratio, 0.83; 95 % CI, 0.76-0.92; p < 0.001; 17 % risk reduction) and clinically meaningful increases in overall pain interference by 2.6 months (median, 10.3 vs 7.7 months; hazard ratio, 0.83; 95 % CI, 0.75-0.92; p < 0.001; 17 % risk reduction) compared with zoledronic acid. Strong opioid use and worsening of health-related quality of life were less common with denosumab.
conclusionsAcross three large studies of patients with advanced solid tumours and bone metastases, denosumab prevented progression of pain severity and pain interference more effectively than zoledronic acid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.